NeuroSense Research Development from 2010 to 2026

NRSNW Stock  USD 0.28  0.03  9.68%   
NeuroSense Therapeutics Research Development yearly trend continues to be fairly stable with very little volatility. Research Development will likely drop to about 4.7 M in 2026. During the period from 2010 to 2026, NeuroSense Therapeutics Research Development regression line of quarterly data had mean square error of 2 T and geometric mean of  1,799,058. View All Fundamentals
 
Research Development  
First Reported
2020-03-31
Previous Quarter
1.3 M
Current Value
1.3 M
Quarterly Volatility
612.2 K
 
Covid
Check NeuroSense Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NeuroSense Therapeutics' main balance sheet or income statement drivers, such as Interest Income of 2.2 K, Depreciation And Amortization of 18.8 K or Interest Expense of 373.3 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 12.14. NeuroSense financial statements analysis is a perfect complement when working with NeuroSense Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with NeuroSense Stock
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

Latest NeuroSense Therapeutics' Research Development Growth Pattern

Below is the plot of the Research Development of NeuroSense Therapeutics Ltd over the last few years. It is NeuroSense Therapeutics' Research Development historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NeuroSense Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Research Development10 Years Trend
Slightly volatile
   Research Development   
       Timeline  

NeuroSense Research Development Regression Statistics

Arithmetic Mean2,661,132
Geometric Mean1,799,058
Coefficient Of Variation91.74
Mean Deviation2,093,818
Median898,000
Standard Deviation2,441,358
Sample Variance6T
Range6.4M
R-Value0.83
Mean Square Error2T
R-Squared0.68
Significance0.000045
Slope399,091
Total Sum of Squares95.4T

NeuroSense Research Development History

20264.7 M
20256.6 M
20245.7 M
20237.3 M
20226.4 M
20213.1 M
20202.5 M

About NeuroSense Therapeutics Financial Statements

NeuroSense Therapeutics investors use historical fundamental indicators, such as NeuroSense Therapeutics' Research Development, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in NeuroSense Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Research Development6.6 M4.7 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for NeuroSense Stock Analysis

When running NeuroSense Therapeutics' price analysis, check to measure NeuroSense Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NeuroSense Therapeutics is operating at the current time. Most of NeuroSense Therapeutics' value examination focuses on studying past and present price action to predict the probability of NeuroSense Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NeuroSense Therapeutics' price. Additionally, you may evaluate how the addition of NeuroSense Therapeutics to your portfolios can decrease your overall portfolio volatility.